Kornimate/medical-research-clean huggingface dataset:
emotional proactive processing in bipolar disorder

Conditions: Bipolar Disorder; Bipolar I Disorder; Bipolar II Disorder

Summary: the main objective of this project is to identify behavioral specificities of the proactive emotional brain among bipolar patients, compared to healthy subjects. these could contribute to some of the emotional processing biases that can be observed in these patients. to achieve this goal, two behavioral tasks will be administer (emotional stroop and emotional stimuli categorization task) to bipolar patients and control subjects, and their performances will be compared.

this is a case-control non-interventional study comparing bipolar patients to matched healthy controls during one assessment visit at the university hospital of grenoble. the experimentation phase takes place in three stages: first, the experimenter collects demographic data (age and level of study, lack of medical history and treatments that may interfere with the task). for bipolar subjects, it also collects the type of bipolarity, the type and date of the last episode, the age of the onset of the disease and the treatment. secondly, the subject performs a classic stroop task lasting 3 to 5 minutes, including instructions. finally, the subject performs the two main tasks: the emotional stroop task lasting about 20 minutes and then the task of emotional stimuli categorization lasting about 15 minutes.

Eligibility criteria:
inclusion criteria: * right-handed * francophones * bipolar disorder diagnosis (for patients) according to dsm-5 / cim-10 criteria * affiliation to the french social security insurance exclusion criteria: * uncorrected perceptual disturbance * psychiatric disorders other than bipolarity as the main psychiatric disorder or a condition which may affect the tasks proposed for the patients' group * subject under legal protection * subject deprived of freedoms by a judicial or administrative decision * drug abuse less than 12 hours before the assessment

Keywords: bipolar disorder emotion cognition stroop proactive emotional processing
shaping neural activity through parenting

Conditions: Depression; Anxiety

Summary: the purpose of this study is to test causal links between dimensions of positive and harsh parenting and children's brain responses to rewards and errors, using a parenting intervention.

depression and anxiety are among the most frequently diagnosed psychological disorders, with persistent patterns of impairment evident from childhood through adulthood. impaired functioning of core brain systems that respond to reward and errors may increase risk for depression and anxiety. importantly, these neural risk markers for depression and anxiety appear to be shaped, at least in part, by environmental input. problematic parenting is a key environmental factor involved in the intergenerational transmission of depression and anxiety. low positive parenting is associated with blunted brain responses to reward and harsh parenting is associated with heightened brain responses to errors. this study uses an evidence-based parenting program to test causal links between dimensions of positive and harsh parenting and children's brain responses to rewards and errors. participants will include 80 6- to 7-year-old children and their mothers who will be randomly assigned to participate in a parenting program (parent child interaction therapy: pcit) or to a waitlist control group, and brain responses to rewards and errors will be assessed pre- and post-intervention.

Eligibility criteria:
inclusion criteria: * child is 6-7 years old * maternal history of anxiety or depression * maternal self-report of low positive/high harsh parenting exclusion criteria: * child has developmental disorder
upadacitinib as a novel treatment for refractory eyelid dermatitis

Conditions: Eyelid Dermatitis

Summary: this study aims to assess the efficacy of upadacitinib in eyelid dermatitis that has not resolved with topical therapies and patch testing.


Eligibility criteria:
inclusion criteria: * individuals age 18-70 years old with eyelid dermatitis for at least two months * failure of at least one topical prescription cream for the eyelid dermatitis (steroid, pimecrolimus, tacrolimus, crisaborole, or ruxolitinib) * women of reproductive potential must agree to using effective contraception during treatment and for 4 weeks following the final dose of upadacitinib. * willing and able participants that provide informed consent * willing and able participants that comply with study activities exclusion criteria: * self-reported history of allergic response to upadacitinib * subject with self-reported history of heart disease, stroke, or neurological conditions * currently taking topical medications for eyelid dermatitis within one week of starting study drug * women who are pregnant, nursing, or who may become pregnant during the study * non-english-speaking subjects * patients with an active serious infection * patients with active tb or latent tb, patients should be tested for tb prior to upadacitinib treatment. * patients with active hbv/hcv or abnormal lab ranges, lab data: hb\<8g/dl, alc\<500 cells/mm3 and anc \<1000 cells/mm3 * patients with a history of malignancy within the last 5 years other than successfully treated nmsc.
prevalence and characterization of pain in rasopathies

Conditions: RASopathy; Costello Syndrome; Cardio-Facio-Cutaneous Syndrome; Noonan Syndrome

Summary: rasopathies are a group of syndromes caused by variants in genes belonging to the ras/mapk pathway. pain is a neglected topic in rasopathies but it is frequently complained by affected individuals.

to detect prevalence and characteristics of pain in rasopathies by using scales, questionnaires, biochemical analysis and neurophysiological assessment tests.

Eligibility criteria:
inclusion criteria: * all individuals with clinical and molecularly confirmed diagnosis of a rasopathy exclusion criteria: * individuals with a rasopathy con confirmed by genetic analysis
developmentally supportive care on neurobehavioral outcome of preterm very low birth weight neonates

Conditions: Very Low Birth Weight Baby

Summary: enrolled neonates will be provided routine supportive care as per existing neonatal intensive care unit (nicu)protocols. this will be carried out in the initial 6 months (0-180 days) of study commencement. this group will serve as control group (group a). during subsequent 6 months (181-360 days) of the study period, enrolled neonates fulfilling the inclusion criteria will be provided routine supportive care and the components of developmentally supportive care (dsc).

enrolled neonates will be provided routine supportive care as per existing nicu protocols. this will be carried out in the initial 6 months (0-180 days) of study commencement. this group will serve as control group (group a). during subsequent 6 months (181-360 days) of the study period, enrolled neonates fulfilling the inclusion criteria will be provided routine supportive care and the components of developmentally supportive care (dsc). dsc components will be strictly emphasized on protected sleep, pain and stress assessment and management, activities of daily living (positioning, feeding and skin care), the healing environment. this group will be designated as group b. both the groups will receive appropriate management for their morbidities as per existing nicu protocols. both the groups will be followed up till 37 weeks of gestation where in their neurobehavioral assessment will be performed using neurobehavioural assessment of preterm infants score. in both the groups all the baseline data regarding antenatal factors will be recorded in a predesigned proforma such as age, gravid, gestational age, chorioamnionitis, prenatal steroids, multiple pregnancy, maternal comorbidities (preeclampsia, gestational diabetes mellitus), mode of delivery etc.

Eligibility criteria:
inclusion criteria: * all stable preterm very low birth weight babies not on invasive mechanical ventilation * hemodynamically stable * parental consent exclusion criteria: * babies with major congenital anomalies * asphyxia (apgar score \<3 at 5mins). * acute bilirubin encephalopathy * hypoglycemia at enrollment * clinical chorioamnionitis(fever \> 100.4 ◦ f , uterine fundal tenderness, maternal tachycardia (\>100/min), fetal tachycardia (\>160/min) and purulent or foul amniotic fluid ) * history of birth trauma

Keywords: developmentally supportive care
study to assess the efficacy of the itind in subjects with symptomatic bph

Conditions: BPH

Summary: a total of up to 200 symptomatic bph subjects subjects will be enrolled into the study. study duration will be 12 months post implantation with a follow-up visits at year 2 and year 3.

primary study objective: the study's primary objective is to assess the efficacy of the medi-tate itind in subjects with symptomatic bph by reduction of ipss) (international prostate symptoms score) score. secondary study objectives: * to further evaluate the efficacy of medi-tate itind as determined by increase of maximal urinary peak flow, satisfaction from the device and procedures, sex performance capabilities and ejaculation. * safety will be assessed by the rate of complications attributed to the medi-tate itind and its implantation/retrieval procedures.

Eligibility criteria:
inclusion criteria: subject signed informed consent prior to the performance of any study procedures. * male with symptomatic bph: ipss symptom severity score ≥ 10 * peak urinary flow of \< 12 ml/sec at flowmetry with minimum voided volume of at least 120 cc. * prostate volume 25 ml to 80 ml (as assessed by trus) * subject that is able to complete the study protocol * normal urinalysis and urine culture. exclusion criteria: * previous prostate surgery * prostate cancer * urethral stricture * bladder stones * an active urinary tract infection. * obstructing median lobe demonstrated by ipp grade 3 (\>1 cm) as assessed by trus. * neurological conditions potentially affecting voiding function. * a post void residual (pvr) volume \> 250 ml measured by ultrasound * previous diagnosis or treatment for over active bladder * acute urinary retention * any anatomical or physiological condition that in the opinion of the investigator likely to impede successful completion of the study intra-operation exclusion: • obstructing median lobe or any other anatomical or physiological pathology that can interfere the device implantation as assessed by cystoscopy.
anal incontinence and its impact on quality of life and physical activity among hungarian women and the hungarian language validation of the international consultation on incontinence modular questionnaire-bowels (iciq-b)

Conditions: Anal Incontinence

Summary: the aim of the study is to assess the prevalence of anal incontinence among hungarian women who have given birth at least once before, and to examine the impact of anal incontinence on the quality of life and physical activity of these women. a further aim of our study is to adapt the hungarian version of the international consultation on incontinence modular questionnaire - bowels (iciq-b) and to assess its validity and reliability.


Eligibility criteria:
inclusion criteria: * have given birth at least once before * native hungarian language exclusion criteria: * menopause * irritable bowel syndrome (ibs) * chron's disease * ulcerative colitis * developmental abnormalities at the level of the pelvic organs * uninvestigated pelvic pain * malignant pelvic tumor * radiotherapy involving the pelvis * neurological diseases with muscle weakness * parkinson's disease * intellectual disability

Keywords: anal incontinence quality of life physical activity questionnaire
subcutaneous fat reduction in the submental area

Conditions: Body Fat Disorder

Summary: study to evaluate non-invasive subcutaneous fat reduction in the submental area using cryolipolysis. healthy adult men and women with submental skin fold thickness \> 1cm who desire reduction of submental fat.

non-invasive treatment for subcutaneous fat reduction in the submental area.

Eligibility criteria:
inclusion criteria: * male or female subjects \> 22 years of age and \< 65 years of age. * submental skin fold thickness \> 1cm (measured by caliper). * no weight change exceeding 5% of body weight in the preceding month. * agreement to maintain his/her weight (i.e., within 5%) by not making any major changes in diet or exercise routine during the course of the study. * subject has signed a written informed consent form. exclusion criteria: * skin laxity in the neck or chin area for which reduction in submental fat may, in the opinion of the investigator, result in an unacceptable aesthetic result. * prominent platysmal bands at rest which may interfere with assessment of submental fat * evidence of any cause of enlargement in the submental area other than localized subcutaneous fat, such as swollen lymph nodes or ptotic submandibular glands. * significant enlargement on the anterior neck that may prevent the proper placement of the applicator e.g. enlarged thyroid glands. * treatment with dermal fillers, radiofrequency or laser procedures, or chemical peels in the neck or chin area (below the mandible) within the past 6 months. * botulinum toxin or other aesthetic drug injections within the neck or chin area (below the mandible) within the past 6 months. * history of facial nerve paresis or paralysis (such as bell's palsy). * history of a fat reduction procedure (e.g., liposuction, surgery, lipolytic agents, etc.) or implant in or adjacent to the area of intended treatment. * history of prior neck surgery, or prior surgery in the area of intended treatment. * current dental infection. * known history of cryoglobulinemia, cold urticaria, or paroxysmal cold hemoglobinuria. * known history of raynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin. * history of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising. * currently taking or has taken diet pills or weight control supplements within the past month. * any dermatological conditions, such as scars in the location of the treatment area that may interfere with the treatment or evaluation. * active implanted device such as a pacemaker, defibrillator, or drug delivery system. * pregnant or intending to become pregnant in the next 6 months. * lactating or has been lactating in the past 6 months. * unable or unwilling to comply with the study requirements. * currently enrolled in a clinical study of an unapproved investigational drug or device. * any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.
an update on intracerebral hemorrhage

Conditions: Intracerebral Hemorrhage; Stroke; Hematoma

Summary: the intracerebral hemorrhage study is a multicenter , combination of prospective and retrospective observational cohort study led by dr. muhammad junaid akram, phd scholar at chongqing medical university. prof dr. qi li will be the senior consultant for the study. the study will be focusing on natural history, epidemiological , radiological, rehabilitative and clinical aspects as well as the effect of various treatments on the hemorrhagic patients. the study related data of the patients diagnosed with intracerebral hemorrhage will be collected in prospective and retrospective ways. the prognostic data for the patients will be assembled and collected via using different outcome measures at different points of time.

the study will be used to address the several key issues related to intracerebral hemorrhage. the demographics, scores based upon disease severity , mrs, gcs, nihss scores will be recorded at baseline and in the prospective and retrospective ways. the data obtained from the registered patients will be used for future use , critical review by expert neurologists, neurorehabilitative experts for further use and review.

Eligibility criteria:
inclusion criteria: * age \> 18 years patients willing to participate via signing a consent form' patients diagnosed with ct-confirmed spontaneous intracerebral hemorrhage (ich) patients willing to participate in the follow up assessment exclusion criteria: * not willing to participate secondary ich to hemorrhagic infarction or tumor bleeding etc. traumatic ich
impact of race/ethnicity on platelet function

Conditions: Coronary Heart Disease

Summary: the effects of race/ethnicity on platelet function and response to antiplatelet agents will be assessed using healthy participants and coronary heart disease patients from at least 5 racial/ethnic groups.

the effects of race/ethnicity on platelet function and response to antiplatelet agents will be assessed using 125 healthy subjects, 250 coronary heart disease patients treated with aspirin, and 250 coronary heart disease patients treated with aspirin and a p2y12 receptor antagonist, clopidogrel or prasugrel. a minimum of 25 healthy people, 50 people taking only aspirin, and 50 people taking aspirin and clopidogrel/prasugrel will be recruited for at least 5 racial/ethnic groups.

Eligibility criteria:
inclusion criteria: each subject must fulfill the following criteria in order to be included in the study. * the subject must be capable of understanding the nature of the study and executing an informed consent document. * the subject must be aged 19 years or older. * for healthy subjects, the subject must deny taking any medications that affect platelet function for at least 7 days before blood collection. * for diseased patients, subjects with documented cad are eligible to participate if they have been treated with antiplatelet therapy of aspirin (81 to 325 mg/day) with and without clopidogrel (75 mg/day) or another p2y12 antagonist for at least one month. exclusion criteria: for healthy volunteers, subjects who fulfill one or more of the following criteria will be excluded from the study. * taking medications for chronic cardiovascular diseases. * illnesses requiring hospitalization or surgery within the last three months. * history of drug or alcohol abuse. * history of recent anemia or thrombocytopenia. * history of excessive bleeding or thrombosis. * pregnancy. for coronary heart disease subjects, subjects who fulfill one or more of the following criteria will be excluded from the study. * illnesses requiring hospitalization or surgery within the last one month. * history of drug or alcohol abuse. * history of recent anemia or thrombocytopenia. * pregnancy. * recent bleeding diathesis * malignancy * renal insufficiency * liver dysfunction * treatment with warfarin or glycoprotein (gp) iib/iiia antagonists during the preceding 14 days
comparison of the effects of single versus triple injections of platelet-rich plasma in patients with knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: 80 patients diagnosed with knee osteoarthritis were randomized into two groups: patients in group 1 received a single intraarticular injection of prp whereas those in group 2 were administered three intraarticular injections of prp within an interval of 2 weeks between each application. patients were evaluated before the treatment and at the 6 month after the treatment with a visual analog scale (vas) and the western ontario and macmaster universities (womac) osteoarthritis index.


Eligibility criteria:
inclusion criteria: * ages of 35 and 80 * kellgren-lawrence grade of 2, 3, or 4 exclusion criteria: * rheumatic diseases, coagulopathies, severe cardiovascular diseases, local infections, malignancies, immunodeficiency, schizophrenia, mental retardation, anticoagulant therapy, a hemoglobin concentration of 11 g/dl and platelets of 150,000/l, a history of severe trauma, or a history of hyaluronic acid or corticosteroid injection within the previous 6 months
exoskeleton-assisted upper limb rehabilitation after stroke

Conditions: Stroke; Upper Extremity Dysfunction

Summary: in recent studies, it has been observed that robotic devices make a positive contribution to motor recovery and the activities of daily living. however, studies about the effects of stroke rehabilitation with robotic devices are limited. this study aimed to investigate the effect of upper extremity robotic rehabilitation on motor function and quality of life in stroke patients.

stroke survivors have difficulties in participating in activities of daily living due to functional disabilities. the majority of patients after stroke need rehabilitation to gain independence in daily life as the first target. therefore, different treatment approaches are used in stroke rehabilitation. the use of technology in stroke rehabilitation has become very common in recent years. robotic devices used in rehabilitation enhance the healing process by giving patients more intensive and task-oriented exercises. a lot of systematic and meta-analysis studies have shown that robot-assisted devices provide positive motor recoveries, especially in the treatment of upper extremities. however, the optimal timing, duration, and dose of robotic rehabilitation that should be applied after stroke remain uncertain. in the light of this information, this study examines the effects of the robotic device produced for upper limb rehabilitation on daily life activities and motor function.

Eligibility criteria:
inclusion criteria: * having ischemic or hemorrhagic stroke history * being at the age between 40 and 85 * mas (modified ashworth scale) \< 3 for upper extremity * at least 6 months after stroke * participants who agree to participate in the study exclusion criteria: * cardiovascular weakness (severe hypertension, coronary artery disease) * mini-mental state examination score \< 24 * recurrent stroke * having other orthopedic and neurologic conditions that may affect upper extremity movement * having behavioral and cognitive problems

Keywords: stroke upper extremity robotic rehabilitation motor function quality of life